Lilly Collaboration Program(s)
Undisclosed
DiscoveryActive
Key Facts
About BigHat Biosciences
BigHat Biosciences is a private, Series B biotech company leveraging a proprietary integrated platform called Milliner to revolutionize antibody discovery and engineering. The platform synergizes high-throughput synthetic biology labs with advanced machine learning models to design, build, and test hundreds of antibody variants weekly, significantly compressing development timelines. The company has a pipeline of over ten therapeutic programs, engages in strategic partnerships with major pharma, and has raised over $100 million from top-tier investors to advance its mission of creating better biologics faster.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |